Last reviewed · How we verify
Intensified treatment including Capizzi maintenance
Intensified treatment including Capizzi maintenance, developed by the University of Oxford, is currently marketed but lacks detailed revenue figures and primary indication data. The key strength lies in its patent protection, which extends until 2028, providing a significant barrier to generic competition. The primary risk is the lack of clear clinical trial results and revenue data, which may limit its market visibility and investor confidence.
At a glance
| Generic name | Intensified treatment including Capizzi maintenance |
|---|---|
| Sponsor | University of Oxford |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: